Please assess the completion status of the following clinical trial:

Trial Title: Switching to Duloxetine in Patients With Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 18 years or older who meet criteria for Major Depressive Disorder (MDD).~* Currently receiving a selective serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI) class of antidepressant for at least a month for the treatment of depression.~* Females of child-bearing potential (not surgically sterilized and between menarche and 1 year postmenopause) to test negative for pregnancy based on a urine pregnancy test and to agree to use a reliable method of birth control.~Exclusion Criteria:~* Women who are pregnant or plan to be pregnant or are breastfeeding.~* To have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication.~* Diagnosed with treatment resistant depression.~* History of bipolar disorder, schizophrenia, or other psychotic disorders.~* To have previously taken duloxetine that didn't work.~* Judged to be at serious suicidal risk in the opinion of the investigator and/or score \>=3 on Item 3 (suicide) of the 17-Item Hamilton Depression Rating Scale (HAMD-17) at screening (Visit 1) or baseline (Visit 2).~* A serious medical illness that may need treatment during the study.~* Taking certain medications that are not allowed in this study.~* To have a history of alcohol and/or drug abuse or dependence within the past year.~* To have uncontrolled narrow-angle glaucoma.~* To have allergic reactions to many medicines.~* To have undergone shock therapy (Electroconvulsive Therapy) or magnet treatment (Transcranial Magnetic Stimulation) within the past year.~* To initiate talk therapy (psychotherapy) just before or during the study.~* To have chronic pain and you have been taking medicine for it for the last 6 months.~* To have certain liver diseases.~* To have kidney disease or undergoing dialysis.~* Abnormal thyroid stimulating hormone (TSH) concentration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Duloxetine (Type: EXPERIMENTAL): Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).